Neoplasm

In this 2023 study the authors included 4 cases of acinic cell carcinoma of the salivary gland. The age of the patients ranged from 13 to 16 years, and included 2 males and 2 females. Immunohistochemi… (full text at CIViC)

PMID 36169793 · Cole et al., 2023 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

Among pediatric fibroblastic and myofibroblastic proliferating superficial lesions, lipofibromatosis (LPF), composed of an admixture of adipose tissue and fibroblastic elements, has been variously cla… (full text at CIViC)

PMID 27259011 · Agaram et al., 2016 · Open in CIViC

Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In the STARTRK-NG (NCT02650401) phase 1/2 trial, 43 pediatric and young adult patients (age <22 years) with recurrent or refractory solid tumors, including primary CNS tumors, were evaluated for respo… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Two new NTRK2 fusion events were identified in this study. These two NTRK2 fusion events, namely QKI-NTRK2 (2 of 96 samples) and NACC2… (full text at CIViC)

PMID 23817572 · Jones et al., 2013 · Open in CIViC

54 patients aged 18 or older with metastatic or locally advanced NTRK-fusion positive solid tumours (including ten tumour types and 19 unique histologies) were enrolled in one of three phase 1 or 2 tr… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the a… (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In this 2020 study, the authors included a total of 141 NUT carcinomas defined by rearrangement of NUTM1 detected by IHC, cytogenetics, FISH or sequencing. The median age at diagnosis was 24 years (ra… (full text at CIViC)

PMID 32328562 · Chau et al., 2020 · Open in CIViC

In this 2004 study, the authors sought to identify carcinomas with translocation t(15;19)(q13, p13.1), which results in the novel oncogenic fusion BRD4::NUTM1 (described as NUT). The authors screened … (full text at CIViC)

PMID 15483023 · French et al., 2004 · Open in CIViC

Next generation sequencing was performed on 35023 Chinese cases with 13 different solid tumor types. EGFR Fusions were detected in 106 samples. All EGFR fusions contained the complete tyrosine kinase … (full text at CIViC)

PMID 39054543 · Zhang et al., 2024 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusi… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated wit… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

Using next-generation DNA and RNA sequencing, three cases harboring NTRK fusions were identified in a cohort of 113 osteosarcomas (including primary tumors and metastases). Each of the three cases had… (full text at CIViC)

PMID 32022484 · Ameline et al., 2020 · Open in CIViC

The authors describe the creation of a data portal containing over 20,000 gene fusions identified in 9,966 cancer samples and 648 normal samples from The Cancer Genome Atlas. The VPS18-NTRK3 e4::e18 f… (full text at CIViC)

PMID 29099951 · Hu et al., 2018 · Open in CIViC

Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro.

PMID 22016507 · Wittinger et al., 2011 · Open in CIViC

Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had receive… (full text at CIViC)

PMID 27544060 · Lin et al., 2016 · Open in CIViC

RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC)

PMID 27825636 · Drilon et al., 2016 · Open in CIViC